Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

Douglas M. Herrin, Emily E. Coates, Pamela J. Costner, Troy J. Kemp, Martha C. Nason, Kapil K. Saharia, Yuanji Pan, Uzma N. Sarwar, Lasonji Holman, Galina Yamshchikov, Richard A. Koup, Yuk Ying S Pang, Robert A. Seder, John T. Schiller, Barney S. Graham, Ligia A. Pinto, Julie E. Ledgerwood

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix® or Gardasil®, followed 6 month vaccination delivery schedules per manufacturer's recommendations, and analyzed the humoral immune response, T cell response, and circulating plasma cytokine levels in response to vaccination. Cervarix® recipients had higher anti-HPV-16 antibody and neutralization titers at month 7, and elevated anti-HPV-18 antibody and neutralization titers at months 7 and 12. Antibody avidity was similar for the 2 vaccines. HPV-31 was the only phylogenetically related non-vaccine HPV type, for which there is evidence of cross-protection, to be cross-neutralized and only in response to Cervarix®. Comparing CD4+ T cell cytokine responses at month 12, there was a trend of increased levels of IL-2 and TNF-a in the Cervarix® groups versus the Gardasil® groups that was consistent across all 4 tested HPV types (16/18/33/45). Elevated levels of circulating plasma cytokine/chemokines were observed post first vaccination in Gardasil® recipients and proinflammatory cytokines were elevated following 1st and 3rd Cervarix® vaccinations. Cervarix® and Gardasil® are both highly immunogenic vaccines. Higher antibody levels and CD4 T cell responses were achieved with Cervarix® after 3 doses, although similar affinity maturation was measured for the 2 vaccines. The clinical implications of the differences in immune responses are unknown.

Original languageEnglish (US)
Pages (from-to)3446-3454
Number of pages9
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
Adaptive Immunity
Innate Immunity
Human papillomavirus 18
Human papillomavirus 16
Vaccination
Vaccines
Cytokines
T-Lymphocytes
Antibodies
Human papillomavirus 31
Virus-Like Particle Vaccines
Cross Protection
Human papillomavirus 11
Human papillomavirus 6
Antibody Affinity
human papillomavirus vaccine, L1 type 16, 18
Humoral Immunity
Chemokines
Interleukin-2

Keywords

  • Adaptive immunity
  • Adjuvant
  • Human papillomavirus vaccine
  • Immune signatures
  • Innate immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Herrin, D. M., Coates, E. E., Costner, P. J., Kemp, T. J., Nason, M. C., Saharia, K. K., ... Ledgerwood, J. E. (2014). Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. Human Vaccines and Immunotherapeutics, 10(12), 3446-3454. https://doi.org/10.4161/hv.34408

Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. / Herrin, Douglas M.; Coates, Emily E.; Costner, Pamela J.; Kemp, Troy J.; Nason, Martha C.; Saharia, Kapil K.; Pan, Yuanji; Sarwar, Uzma N.; Holman, Lasonji; Yamshchikov, Galina; Koup, Richard A.; Pang, Yuk Ying S; Seder, Robert A.; Schiller, John T.; Graham, Barney S.; Pinto, Ligia A.; Ledgerwood, Julie E.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 12, 01.12.2014, p. 3446-3454.

Research output: Contribution to journalArticle

Herrin, DM, Coates, EE, Costner, PJ, Kemp, TJ, Nason, MC, Saharia, KK, Pan, Y, Sarwar, UN, Holman, L, Yamshchikov, G, Koup, RA, Pang, YYS, Seder, RA, Schiller, JT, Graham, BS, Pinto, LA & Ledgerwood, JE 2014, 'Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus', Human Vaccines and Immunotherapeutics, vol. 10, no. 12, pp. 3446-3454. https://doi.org/10.4161/hv.34408
Herrin, Douglas M. ; Coates, Emily E. ; Costner, Pamela J. ; Kemp, Troy J. ; Nason, Martha C. ; Saharia, Kapil K. ; Pan, Yuanji ; Sarwar, Uzma N. ; Holman, Lasonji ; Yamshchikov, Galina ; Koup, Richard A. ; Pang, Yuk Ying S ; Seder, Robert A. ; Schiller, John T. ; Graham, Barney S. ; Pinto, Ligia A. ; Ledgerwood, Julie E. / Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. In: Human Vaccines and Immunotherapeutics. 2014 ; Vol. 10, No. 12. pp. 3446-3454.
@article{00ba0166f5eb40869883534d0c34f3f8,
title = "Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus",
abstract = "Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix{\circledR}) and HPV-6/11/16/18 (Merck, Gardasil{\circledR}), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix{\circledR} or Gardasil{\circledR}, followed 6 month vaccination delivery schedules per manufacturer's recommendations, and analyzed the humoral immune response, T cell response, and circulating plasma cytokine levels in response to vaccination. Cervarix{\circledR} recipients had higher anti-HPV-16 antibody and neutralization titers at month 7, and elevated anti-HPV-18 antibody and neutralization titers at months 7 and 12. Antibody avidity was similar for the 2 vaccines. HPV-31 was the only phylogenetically related non-vaccine HPV type, for which there is evidence of cross-protection, to be cross-neutralized and only in response to Cervarix{\circledR}. Comparing CD4+ T cell cytokine responses at month 12, there was a trend of increased levels of IL-2 and TNF-a in the Cervarix{\circledR} groups versus the Gardasil{\circledR} groups that was consistent across all 4 tested HPV types (16/18/33/45). Elevated levels of circulating plasma cytokine/chemokines were observed post first vaccination in Gardasil{\circledR} recipients and proinflammatory cytokines were elevated following 1st and 3rd Cervarix{\circledR} vaccinations. Cervarix{\circledR} and Gardasil{\circledR} are both highly immunogenic vaccines. Higher antibody levels and CD4 T cell responses were achieved with Cervarix{\circledR} after 3 doses, although similar affinity maturation was measured for the 2 vaccines. The clinical implications of the differences in immune responses are unknown.",
keywords = "Adaptive immunity, Adjuvant, Human papillomavirus vaccine, Immune signatures, Innate immunity",
author = "Herrin, {Douglas M.} and Coates, {Emily E.} and Costner, {Pamela J.} and Kemp, {Troy J.} and Nason, {Martha C.} and Saharia, {Kapil K.} and Yuanji Pan and Sarwar, {Uzma N.} and Lasonji Holman and Galina Yamshchikov and Koup, {Richard A.} and Pang, {Yuk Ying S} and Seder, {Robert A.} and Schiller, {John T.} and Graham, {Barney S.} and Pinto, {Ligia A.} and Ledgerwood, {Julie E.}",
year = "2014",
month = "12",
day = "1",
doi = "10.4161/hv.34408",
language = "English (US)",
volume = "10",
pages = "3446--3454",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

AU - Herrin, Douglas M.

AU - Coates, Emily E.

AU - Costner, Pamela J.

AU - Kemp, Troy J.

AU - Nason, Martha C.

AU - Saharia, Kapil K.

AU - Pan, Yuanji

AU - Sarwar, Uzma N.

AU - Holman, Lasonji

AU - Yamshchikov, Galina

AU - Koup, Richard A.

AU - Pang, Yuk Ying S

AU - Seder, Robert A.

AU - Schiller, John T.

AU - Graham, Barney S.

AU - Pinto, Ligia A.

AU - Ledgerwood, Julie E.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix® or Gardasil®, followed 6 month vaccination delivery schedules per manufacturer's recommendations, and analyzed the humoral immune response, T cell response, and circulating plasma cytokine levels in response to vaccination. Cervarix® recipients had higher anti-HPV-16 antibody and neutralization titers at month 7, and elevated anti-HPV-18 antibody and neutralization titers at months 7 and 12. Antibody avidity was similar for the 2 vaccines. HPV-31 was the only phylogenetically related non-vaccine HPV type, for which there is evidence of cross-protection, to be cross-neutralized and only in response to Cervarix®. Comparing CD4+ T cell cytokine responses at month 12, there was a trend of increased levels of IL-2 and TNF-a in the Cervarix® groups versus the Gardasil® groups that was consistent across all 4 tested HPV types (16/18/33/45). Elevated levels of circulating plasma cytokine/chemokines were observed post first vaccination in Gardasil® recipients and proinflammatory cytokines were elevated following 1st and 3rd Cervarix® vaccinations. Cervarix® and Gardasil® are both highly immunogenic vaccines. Higher antibody levels and CD4 T cell responses were achieved with Cervarix® after 3 doses, although similar affinity maturation was measured for the 2 vaccines. The clinical implications of the differences in immune responses are unknown.

AB - Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix® or Gardasil®, followed 6 month vaccination delivery schedules per manufacturer's recommendations, and analyzed the humoral immune response, T cell response, and circulating plasma cytokine levels in response to vaccination. Cervarix® recipients had higher anti-HPV-16 antibody and neutralization titers at month 7, and elevated anti-HPV-18 antibody and neutralization titers at months 7 and 12. Antibody avidity was similar for the 2 vaccines. HPV-31 was the only phylogenetically related non-vaccine HPV type, for which there is evidence of cross-protection, to be cross-neutralized and only in response to Cervarix®. Comparing CD4+ T cell cytokine responses at month 12, there was a trend of increased levels of IL-2 and TNF-a in the Cervarix® groups versus the Gardasil® groups that was consistent across all 4 tested HPV types (16/18/33/45). Elevated levels of circulating plasma cytokine/chemokines were observed post first vaccination in Gardasil® recipients and proinflammatory cytokines were elevated following 1st and 3rd Cervarix® vaccinations. Cervarix® and Gardasil® are both highly immunogenic vaccines. Higher antibody levels and CD4 T cell responses were achieved with Cervarix® after 3 doses, although similar affinity maturation was measured for the 2 vaccines. The clinical implications of the differences in immune responses are unknown.

KW - Adaptive immunity

KW - Adjuvant

KW - Human papillomavirus vaccine

KW - Immune signatures

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=84922575278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922575278&partnerID=8YFLogxK

U2 - 10.4161/hv.34408

DO - 10.4161/hv.34408

M3 - Article

VL - 10

SP - 3446

EP - 3454

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 12

ER -